Cost-Effectiveness Analysis : Controlled-Release Nifedipine and Valsartan Combination Therapy in Patients with Essential Hypertension : The Adalat CR and Valsartan Cost-Effectiveness Combination (ADVANCE-Combi) Study

• SAITO Ikuo

  Health Center, Keio University

• FUJIKAWA Keita

  Product Development Division, Bayer Yakuhin, Ltd.

• SARUTA Takao

  Internal Medicine, School of Medicine, Keio University

• ADVANCE-Combi Study Group

収録刊行物

• Hypertension research : clinical and experimental : official journal of the Japanese Society of Hypertension

  Hypertension research : clinical and experimental : official journal of the Japanese Society of Hypertension 31 (7), 1399-1405, 2008-07-01

キーワード

• essential hypertension
• controlled-release nifedipine
• valsartan
• amlodipine
• incremental cost-effectiveness

詳細情報

• CRID: 1573668925492217472
• NII論文ID: 10024360941
• NII書誌ID: AA10847079
• ISSN: 09169636
• Web Site: https://search.jamas.or.jp/link/ui/2009058845
• 本文言語コード: en
• データソース種別:
  • CiNii Articles